General Bio, a developer of oral GLP-1s and other peptides, has raised $7.4 million and is pursuing a larger funding round, CEO David Kim tells Axios exclusively.
Why it matters: The company is entering an increasingly competitive market with a lower-cost manufacturing pitch.
